UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For

the quarterly period ended April 3, 2005

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE NUMBER

1-3619

----

PFIZER

INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street,

New York, New York 10017

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1)

has filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X

NO

Indicate by check mark whether the registrant is an

accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

YES X

NO

At May 3, 2005, 7,435,344,024 shares of the

issuer's voting common stock were outstanding.

FORM

10-Q

For the

Quarter Ended

April 3, 2005

Table

of Contents

PART

I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements:

Condensed Consolidated

Statement of Income for the three months ended April 3, 2005 and March 28,

2004

Condensed Consolidated

Balance Sheet at April 3, 2005 and December 31, 2004

Condensed Consolidated

Statement of Cash Flows for the three months ended April 3, 2005 and March 28,

2004

Notes to Condensed

Consolidated Financial Statements

Review Report of Independent

Registered Public Accounting Firm

16

Item 2.

Management's Discussion

and Analysis of Financial Condition and Results of Operations

17

Item 4.

Controls and Procedures

37

PART

II. OTHER INFORMATION

Item 1.

Legal Proceedings

38

Item 2.

Unregistered Sales of

Equity Securities and Use of Proceeds

38

Item 4.

Submission of Matters

to a Vote of Security Holders

39

Item 6.

Exhibits

40

Signature

41

Certifications

44

PART

I. FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC AND SUBSIDIARY

COMPANIES

CONDENSED CONSOLIDATED STATEMENT OF INCOME

(UNAUDITED)

Three Months

Ended

(millions of dollars, except per common share data)

April 3,

2005

March 28,

2004

Revenues

13,091

12,487

Costs and expenses:

Cost of sales(1)

2,191

1,794

Selling, informational

and administrative expenses(1)

4,085

3,933

Research and development

expenses(1)

1,764

1,649

Amortization of

intangible assets

882

823

Merger-related

in-process research and development charges

955

Merger-related costs

219

247

Other

(income)/deductions-net

1,038

(43)

Income from

continuing operations before provision for taxes on income, and minority

interests

2,910

3,129

Provision for taxes on

income

2,635

809

Minority interests

Income from

continuing operations

272

2,318

Discontinued operations:

Income/(loss) from discontinued

operations-net of tax

(12)

13

Gains on sales of

discontinued operations-net of tax

41

--

Discontinued

operations-net of tax

29

13

Net income

301

2,331

Earnings per common share - Basic:

Income from

continuing operations

.04

.31

Discontinued

operations-net of tax

--

--

Net income

.04

.31

Earnings per common share - Diluted:

Income from

continuing operations

.04

.30

Discontinued

operations-net of tax

--

--

Net income

.04

.30

Weighted-average shares

used to calculate earnings per common share:

Basic

7,416

7,586

Diluted

7,474

7,679

Cash dividends paid per common share

.19

.17

(1)

Exclusive of amortization of intangible assets,

except as disclosed in Note 9B, Goodwill

and Other Intangible Assets: Other Intangible Assets.

See accompanying Notes to

Condensed Consolidated Financial Statements.

PFIZER INC AND SUBSIDIARY

COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEET

(UNAUDITED)

(millions of dollars)

April 3,

2005*

Dec. 31,

2004**

ASSETS

Current Assets

Cash and cash

equivalents

1,476

1,808

Short-term investments

20,495

18,085

Accounts receivable,

less allowance for doubtful accounts: $214 and $205

10,074

9,367

Short-term loans

587

653

Inventories

6,551

6,660

Prepaid expenses and taxes

2,792

2,939

Assets held for sale

378

182

Total current assets

42,353

39,694

Long-term investments

and loans

3,619

3,873

Property, plant and

equipment, less accumulated depreciation: $8,682 and $8,534

17,912

18,385

Goodwill

23,671

23,756

Identifiable intangible

assets, less accumulated amortization

31,001

33,251

Other assets, deferred

taxes and deferred charges

4,379

4,725

Total assets

122,935

123,684

LIABILITIES AND

SHAREHOLDERS' EQUITY

Current Liabilities

Short-term borrowings,

including current portion of long-term debt: $1,390 and $907

13,399

11,266

Accounts payable

2,300

2,672

Dividends payable

1,418

Income taxes payable

5,288

1,963

Accrued compensation

and related items

1,601

1,939

Other current

liabilities

6,315

7,136

Liabilities held for

sale

42

64

Total current liabilities

28,948

26,458

Long-term debt

6,432

7,279

Pension benefit

obligations

2,897

2,821

Postretirement benefit

obligations

1,448

1,450

Deferred taxes on

income

12,737

12,632

Other noncurrent

liabilities

2,941

4,766

Total liabilities

55,403

55,406

Shareholders' Equity

Preferred stock

187

193

Common stock

438

438

Additional paid-in

capital

67,096

67,098

Retained earnings

35,785

35,492

Accumulated other

comprehensive income

1,909

2,278

Employee benefit trust,

at fair value

(1,002)

(1,229)

Treasury stock

(36,881)

(35,992)

Total shareholders' equity

67,532

68,278

Total liabilities and shareholders' equity

122,935

123,684

* Unaudited.

** Condensed from audited financial

statements.

See accompanying Notes to

Condensed Consolidated Financial Statements.

PFIZER INC AND SUBSIDIARY

COMPANIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(UNAUDITED)

Three Months

Ended

(millions of dollars)

April 3,

2005

March 28,

2004

Operating

Activities:

Net income

301

2,331

Adjustments to reconcile

net income to net cash provided by continuing operating activities:

Income from discontinued

operations

(29)

(13)

Depreciation and

amortization

1,366

1,261

Merger-related

in-process research and development charges

955

Asset impairment charge

and other costs associated with the suspension of Bextra sales

1,213

--

Deferred taxes

484

(284)

Other

96

174

Changes in assets and

liabilities (net of businesses acquired and divested)

(259)

(2,841)

Net cash provided by continuing operating activities

3,174

1,583

Investing Activities:

Purchases of property,

plant and equipment

(465)

(472)

Purchases of short-term

investments

(4,891)

(4,603)

Proceeds from

redemptions of short-term investments

2,550

2,613

Purchases of long-term

investments

(494)

(453)

Proceeds from sales of

long-term investments

437

816

Purchases of other

assets

(70)

(153)

Proceeds from sales of

other assets

--

109

Acquisition of

businesses, net of cash acquired

--

(1,443)

Proceeds from the sales

of businesses and product lines

93

--

Other investing

activities

154

(135)

Net cash used in investing activities

(2,686)

(3,721)

Financing Activities:

Increase in short-term borrowings,

net

1,591

1,776

Decrease in short-term borrowings,

net

(205)

(106)

Proceeds from issuances

of long-term debt

1,524

Principal payments on

long-term debt

(1)

(3)

Proceeds from common

stock issuances

20

17

Purchases of common

stock

(919)

(912)

Cash dividends paid

(1,400)

(1,282)

Stock option

transactions and other

95

569

Net cash (used in)/provided

by financing activities

(818)

1,583

Net cash provided by

discontinued operations

--

--

Effect of exchange-rate

changes on cash and cash equivalents

(2)

--

Net decrease in cash and

cash equivalents

(332)

(555)

Cash and cash

equivalents at beginning of period

1,808

1,520

Cash and cash

equivalents at end of period

1,476

965

Supplemental Cash

Flow Information:

Cash paid during the

period for:

Income taxes

557

796

Interest

141

69

See accompanying Notes to

Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1: Basis of Presentation

We prepared the condensed consolidated financial statements following

the requirements of the Securities and Exchange Commission (SEC) for interim

reporting. As permitted under those rules, certain footnotes or other financial

information that are normally required by accounting principles generally

accepted in the United States of America (GAAP) can be condensed or omitted.

Balance sheet amounts and operating results for subsidiaries operating outside

the U.S. are as of and for the three-month periods ended February 27, 2005 and February

22, 2004. The fiscal first quarter of 2005 had three additional business days

compared to the fiscal first quarter of 2004.

We are responsible for the unaudited financial statements included in

this document. The financial statements include all normal and recurring

adjustments that are considered necessary for the fair presentation of our

financial position and operating results.

Revenues, expenses, assets and liabilities can vary during each quarter

of the year. Therefore, the results and trends in these interim financial

statements may not be representative of those for the full year.

The information included in this Quarterly Report on Form 10-Q should

be read in conjunction with the consolidated financial statements and

accompanying notes included in Pfizer's Annual Report on Form 10-K for the

year ended December 31, 2004.

In accordance with Statement of Financial Accounting Standards (SFAS)

No. 123, Accounting for Stock-Based

Compensation, we elected to account for our stock-based compensation

under Accounting Principles Board Opinion (APB) No. 25, Accounting for Stock Issued to Employees.

The exercise price of stock options granted equals the market price on the date

of grant. There is no recorded expense related to grants of stock options.

The weighted-average fair

value per stock option granted was $5.15 for the three months ended April 3,

2005, and $6.88 for the three months ended March 28, 2004. We estimated the

fair values, as required under GAAP, using the Black-Scholes option-pricing

model, modified for dividends and using the assumptions below. In the first

quarter of 2005, we changed our method of estimating expected dividend yield

from historical patterns of dividend payments to a method that reflects a

constant dividend yield during the expected term of the option.

Three Months

Ended

April 3,

2005

March 28,

2004

Expected dividend yield

2.90%

2.90%

Risk-free interest rate

3.96%

3.32%

Expected stock price volatility

21.93%

22.15%

Expected term until exercise (years)

5.75

5.75

The following table

summarizes our results for the three-month periods ended April 3, 2005 and

March 28, 2004 as if we had recorded compensation expense for the option

grants:

Three Months

Ended

(millions of dollars, except per common share data)

April 3,

2005

March 28,

2004

Net income available to

common shareholders used in the calculation of basic earnings per common

share:

As reported under GAAP*

299

2,330

Compensation expense

(147)

(126)

Pro forma

152

2,204

Basic earnings per

common share:

As reported under GAAP*

.04

.31

Compensation expense

(.02)

(.02)

Pro forma

.02

.29

Net income available to

common shareholders used in the calculation of diluted earnings per common

share:

As reported under GAAP*

300

2,330

Compensation expense

(147)

(126)

Pro forma

153

2,204

Diluted earnings per

common share:

As reported under GAAP*

.04

.30

Compensation expense

(.02)

(.01)

Pro forma

.02

.29

Includes stock-based compensation expense, net of

related tax benefits of $15 million for the three months ended April 3,

2005 and $29 million for the three months ended March 28, 2004.

Net income available to common shareholders used in the calculation of

basic earnings per common share represents net income reduced by preferred

stock dividends-net of tax. Net income available to common shareholders used in

the calculation of diluted earnings per common share represents net income

reduced by the incremental allocation of shares to the Employee Stock Ownership

Plans (ESOPs) acquired as part of the Pharmacia acquisition.

Note 2: Asset Impairment Charge and Other Costs Associated with the Suspension

of Bextra Sales

In the first quarter of 2005, we recorded charges totaling

$1,213 million ($766 million net of tax) in connection with the decision

to suspend sales and marketing of Bextra.

On April 7, 2005, as

part of the U.S. Food and Drug Administration's (FDA) safety review of all COX-2

medicines, which began in late 2004 and included a mid-February 2005 meeting of

the FDA Arthritis Advisory Committee and the Drug Safety and Risk Management

Advisory Committee, the FDA requested the suspension of Bextra sales and

marketing.

The pre-tax charges

included $1,145 million related to the impairment of developed technology

rights associated with Bextra and $10 million related to the write-off of

machinery and equipment, both of which are included in Other income/(deductions)-net; $56 million

in write-offs of inventory, included in Cost

of sales; and $2 million related to the costs of administering

the suspension of sales, included in Selling,

informational and administrative expenses. In addition, we recorded

a net charge of $71 million, substantially against Revenues, for estimated customer returns.

Note 3: Income Taxes

In the first quarter of 2005, we recorded an income tax charge of

$2,189 million, included in Provisions

for taxes on income, in connection with our decision to repatriate

$28.3 billion of foreign earnings in accordance with the American Jobs Creation Act of 2004 (the

Act). This tax charge may be reduced by approximately $850 million in

future periods due to technical corrections legislation expected to be

considered in 2005.

The amount of foreign earnings to be repatriated pursuant to the Act

could be increased by up to $10.6 billion, subject to future guidance from

the U.S. Treasury. We expect the future guidance to clarify whether the unremitted

earnings of companies acquired after December 31, 2002 are eligible for

repatriation, as well as address the methodology under which unremitted

earnings are allocated among members of a group for financial statement

purposes which are not also part of the same consolidated tax group. Based on

information presently available, the income tax effects of such additional

repatriation could be up to $750 million.

As of April 3, 2005, we intend to continue to reinvest the earnings

of our international subsidiaries overseas and, therefore, we have not recorded

a U.S. tax provision on the remaining amount of unremitted earnings of our

international subsidiaries.

Note 4: Merger-Related

Costs

We incurred the following

merger-related costs primarily in connection with our acquisition of Pharmacia

Corporation (Pharmacia) which was completed on April 16, 2003:

Three Months

Ended

(millions of dollars)

April 3,

2005

March 28,

2004

Integration costs

106

104

Restructuring costs

113

143

Total merger-related

costs - expensed

219

247

In connection with the acquisition of Pharmacia, Pfizer management has approved

plans to restructure and integrate the operations of both legacy Pfizer and

legacy Pharmacia to combine operations, eliminate duplicative facilities and

reduce costs. The restructuring of our operations as a result of our

acquisition of Pharmacia is expected to continue through 2005 and is expected

to include consulting, systems integrations, severance, costs of vacating

duplicative facilities, contract termination and other exit costs.

Total merger-related expenditures expected to be incurred during 2003-2005

to achieve anticipated synergies are about $6.0 billion, on a pre-tax

basis. The remaining costs expected to be incurred are primarily associated

with asset impairments, exit costs and employee terminations.

Restructuring Costs

Through April 15,

2004, we recorded restructuring costs associated with employee terminations and

exiting certain activities of legacy Pharmacia. These costs were recognized as

liabilities assumed in the purchase business combination. Accordingly, the

restructuring costs incurred in the first year after the acquisition were

considered part of the purchase price of Pharmacia and were recorded as an

increase to goodwill. These restructuring costs also included costs associated

with relocation. Changes to previous estimates of restructuring costs included

as part of the purchase allocation of Pharmacia are recorded as a reduction to

goodwill or an expense to operations, as appropriate. Restructuring costs

incurred for legacy Pfizer and restructuring costs incurred after

April 15, 2004 for legacy Pharmacia are charged to the results of

operations.

The components of restructuring

costs follow:

(millions of dollars)

Total

Utilization

Through

April 3,

2005

(a)

Reserve*

April 3,

2005

Costs capitalized through April 15, 2004:

Employee termination

costs

1,535

1,484

51

Other

624

482

142

2,159

1,966

193

Costs expensed:

Employee termination

costs

569

431

138

Asset impairments

341

341

--

Other

84

45

39

994

817

177

Included in Other

current liabilities.

(a)

Includes insignificant adjustments to original

amounts established.

During the first quarter of 2005, we expensed $52 million for Employee termination costs, $51 million

for Asset impairments and $10 million

in Other. Through April 3, 2005, Employee termination costs represent the

approved reduction of the legacy Pfizer and legacy Pharmacia work force by

16,937 employees, mainly in corporate, manufacturing, distribution, sales

and research. We notified affected individuals and 15,676 employees were

terminated as of April 3, 2005. Employee

termination costs include accrued severance benefits and costs

associated with change-in-control provisions of certain Pharmacia employment

contracts. Asset impairments primarily

include charges to write-down property, plant and equipment. Other primarily includes costs to exit

certain activities of legacy Pfizer and legacy Pharmacia.

Note 5: Discontinued Operations

We evaluate our

businesses and product lines on an ongoing basis for strategic fit within our

operations. As a result of our evaluation, in the first quarter of 2004, we

decided to sell our in-vitro allergy and autoimmune diagnostics testing

(Diagnostics) business, formerly included in the "Corporate/Other"

category; our surgical ophthalmic business, formerly included in our Human

Health segment; certain non-core consumer product lines marketed primarily in

Europe, formerly included in our Consumer Healthcare segment; and certain

European generic pharmaceutical businesses, formerly included in our Human

Health segment. All of these sales were completed in 2004, except for the sale

of two European generic pharmaceutical businesses. The revenues associated with

the discontinued operations were $15 million in the first quarter of 2005

and $150 million in the first quarter of 2004.

In the first quarter of 2005, we sold one of the two remaining European

generic pharmaceutical businesses for 70 million euro ($93 million) and

recognized a gain of $57 million ($36 million net of tax). In

connection with the expected sale of the remaining European generic business, we

recorded an additional impairment of $9 million ($6 million net of